AstraZeneca and Ceram Sign R&D Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca and Ceram Sign R&D Agreement


ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.

In a statement, Ceram CEO, Tony Kinsella, said, “This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds.”

Ceram said that controlled release is just one of the technologies being worked on by the company’s experts. Other projects involve multielement substituted hydroxyapatite for orthopaedic device coating applications. In addition, Cerma is hoping to expand its business into the US and Europe.

“Our work is focussed on commercial development of materials for industrial applications,” said Kinsella. “We have, for example, recently helped Greatbatch Medical to gain FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here